Empagliflozin after Acute Myocardial Infarction | NEJM
ฝัง
- เผยแพร่เมื่อ 24 เม.ย. 2024
- SGLT2 inhibitors improve cardiovascular outcomes in high-risk patients with diabetes, chronic kidney disease, or heart failure, but their effects after acute myocardial infarction are unknown.
Research findings are summarized in a new Quick Take video.
To see the full article, follow this link: nej.md/4cEb6EB
#cardiology #clinicalmedicine #clinicaltrials #nejm - วิทยาศาสตร์และเทคโนโลยี
Thank you, NEJM.
I always thought SGLT 2 are overhyped.
Respected professor when usually you start Sglt2 inhibitors in your practice in a patient with acute mi , like immediately or after 24 hours or after 72 hours or during discharge, when you want to prefer the Sglt2 inhibitor professor, thank you in anticipation.
There are many limitations in this study